Results 141 to 150 of about 34,485 (247)

Treating schizophrenia symptoms with an α7 nicotinic agonist, from mice to men

, 2007
Ann Olincy, Karen E. Stevens
openalex   +1 more source

Binding Interactions of NS6740, a Silent Agonist of the α7 Nicotinic Acetylcholine Receptor [PDF]

, 2019
Catriona Emily Wilson Blunt, Dennis A. Dougherty   +1 more
openalex   +1 more source

Baseline characteristics in the SYNCHRONIZE™‐2 randomized phase 3 trial of survodutide, a glucagon receptor/GLP‐1 receptor dual agonist, for obesity in people with type 2 diabetes

Diabetes, Obesity and Metabolism, Volume 28, Issue 2, Page 1490-1498, February 2026.
Abstract Aims Survodutide is an investigational glucagon receptor/glucagon‐like peptide‐1 receptor dual agonist that has shown promise for treating obesity and its complications in Phase 2 trials. Two double‐blind, randomized, global Phase 3 trials are designed to assess the efficacy and safety of survodutide for treatment of obesity—SYNCHRONIZE™‐1 in ...
Sean Wharton, Carel W. le Roux, Biykem Bozkurt, Elke Platz, Gabriele Bleckert, Samina Ajaz Hussain, Martina Brueckmann, Elena Startseva, Isabel M. Kloer, Lee M. Kaplan   +9 more
wiley   +1 more source

Tryptophan metabolite atlas uncovers organ, age, and sex‐specific variations

FEBS Open Bio, Volume 16, Issue 1, Page 52-67, January 2026.
Tryptophan metabolites were analyzed across twelve organs, the central nervous system, and serum in male and female mice at three life stages. We found tissue‐, sex‐, and age‐specific differences, including increased indole‐3‐pyruvate and kynurenine in aging males.
Lizbeth Perez‐Castro, Afshan F. Nawas, Jessica A. Kilgore, Pedro A. S. Nogueira, M.Carmen Lafita‐Navarro, Paul H. Acosta, Roy Garcia, Noelle S. Williams, Maralice Conacci‐Sorrell   +8 more
wiley   +1 more source

Mapping the Agonist Binding Site of the Nicotinic Acetylcholine Receptor [PDF]

, 2000
Deirdre Sullivan, Jonathan B. Cohen
openalex   +1 more source

Efficacy and safety of a selective partial agonist for nociception/orphanin‐FQ peptide (NOP) receptors in patients with insomnia disorder

British Journal of Clinical Pharmacology, Volume 92, Issue 1, Page 172-185, January 2026.
Aims Insomnia is a common sleep disorder, affecting up to 20% of the world population and adversely impacting productivity, health, and overall well‐being. Although pharmacologic options exist to treat insomnia, the health‐related quality of life for patients who are prescribed hypnotics is no higher than for those who are not, revealing a significant ...
Garth T. Whiteside, Ellie He, Manjunath S. Shet, Mingyan Zhou, Maha Ahmad, Stephen C. Harris   +5 more
wiley   +1 more source

L‐Quebrachitol Enhances Sedative Effect of Diazepam Through GABAergic Pathway: Animal and Computational Studies

Brain and Behavior, Volume 16, Issue 1, January 2026.
L‐quebrachitol (LQL) significantly enhanced the sedative effects of diazepam in thiopental sodium‐induced chicks by reducing sleep latency and prolonging duration. Molecular docking revealed LQL's interaction with GABAA receptor (α1 and β2 subunits), supporting a GABAergic mechanism and highlighting its potential as a safe, natural sedative agent ...
Asifa Asrafi, Mohammad Aslam, Md. Sakib Al Hasan, Mohammed Burhan Uddin, Emon Mia, Mohammad Y. Alshahrani, Sumaya Akter Bithi, Mst. Sumaia Akter, Md. Arif Hossain, Md. Torequl Islam   +9 more
wiley   +1 more source

Differential antagonism and tolerance/cross-tolerance among nicotinic acetylcholine receptor agonists

, 2016
Fernando B. de Moura, Lance Richard McMahon   +1 more
openalex   +1 more source

Regulation of Nicotinic Receptor Subtypes Following Chronic Nicotinic Agonist Exposure in M10 and SH‐SY5Y Neuroblastoma Cells [PDF]

, 1998
Ulrika Warpman Berglund, Linda Friberg, Alison Gillespie, Ewa Hellström‐Lindahl, Xiao Zhang, Agneta Nordberg   +5 more
openalex   +1 more source

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Ascending Doses and Dose Titration of Bexicaserin in Healthy Participants in a Randomized, Double‐Blind, Placebo‐Controlled Study

Clinical Pharmacology in Drug Development, Volume 15, Issue 1, January 2026.
Abstract Bexicaserin (LP352) is a selective superagonist of the 5‐hydroxytryptamine 2C (5‐HT2C) receptor currently in development for the treatment of seizures that arise from developmental and epileptic encephalopathies. This phase 1, double‐blind, placebo‐controlled multiple ascending dose (MAD) study assessed the safety, tolerability, and ...
Jonathan Williams, Rosa Chan, Chad Orevillo, Gale O'Connell, Dewey McLin, Shikha Polega, Nuggehally R. Srinivas, Randall Kaye   +7 more
wiley   +1 more source